caa a22 4500 46578982X CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171980 doi (NATIONALLICENCE)springer-10.1007/BF00171980 Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines [Elektronische Daten] [A. Harstrick, J. Casper, H. Köhne-Wömpner, H. Wilke, H. Schmoll, H. Poliwoda] Summary: Though the majority of patients with metastatic nonseminomatous germ cell tumors can be cured by modern combination chemotherapy, for those patients who do not respond to standard therapy additional drugs are needed. The activity of three new anthracycline derivatives, 4-epidoxorubicin, THP-doxorubicin and mitoxantrone against two established human testicular cancer cell lines in comparison to doxorubicin and to cisplatin, vinblastine, bleomycin and ifosfamide was studied in a xenograft model. All drugs were given at equitoxic doses. There were no differences in antitumor activity between the four anthracycline derivatives. In line H 12.1, which is very sensitive to the standard drugs cisplatin, vinblastine, bleomycin and ifosfamide, all four anthracycline derivatives were inferior to these agents. In contrast, in line H 23.1, where all four standard agents showed a significant lower antitumor activity when compared to line H 12.1, the anthracyclines preserved their activity, indicating a lack of cross resistance. Thus the anthracycline derivatives seem to be inferior to the standard drugs as first line treatment but because of apparent lack of cross resistance they deserve further evaluation in refractory germ cell tumors. Kluwer Academic Publishers, 1990 doxorubicin nationallicence 4-epidoxorubicin nationallicence mitoxantrone nationallicence THP-doxorubicin nationallicence testicular tumors nationallicence Harstrick A. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut Casper J. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut Köhne-Wömpner H. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut Wilke H. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut Schmoll H. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut Poliwoda H. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S19-S24 0167-6997 8<S19 1990 8 10637 https://doi.org/10.1007/BF00171980 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171980 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Harstrick A. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut NATIONALLICENCE 700 1- Casper J. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut NATIONALLICENCE 700 1- Köhne-Wömpner H. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut NATIONALLICENCE 700 1- Wilke H. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut NATIONALLICENCE 700 1- Schmoll H. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut NATIONALLICENCE 700 1- Poliwoda H. Dep. Hematology/Oncology, University of Hannover, Medical School, 61, Hannover, FRG aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S19-S24 0167-6997 8<S19 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer